HALTER ROBERT J,HOLCOMB RYAN,WETTSTEIN DANIEL A,SHENDEROVICH MARK D,YUNGAI ASHANTAI J,YAGER KRAIG M,RICHARDS BURT,BARTEL PAUL L,MCLEOD DONALD A,SUZUKI KAZUYUKI,SEBAHAR PAUL R,BURSAVICH MATTHEW GREGORY
申请号：
NZ59982610
公开号：
NZ599826A
申请日:
2010.10.12
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure relates to amino-pyrimidine compounds of formula (I) which selectively inhibit the kinase activities of TBK1 and/or IKK epsilon, wherein the variables shown if formula (I) are as defined in the specification. These compounds may be used in the treatment of inflammation, septic shock, Primary open Angle Glaucoma (POAG), RA, SLE, diseases associated with aberrant accumulation of cytosolic nucleic acids (including Sjogrens syndrome, Aicardi-Goutieres syndrome, subtypes of SLE, chilblain lupus, and RVCL), systemic sclerosis, myositis (including dermatomyositis and polymyositis), psoriasis, COPD, lBD, obesity, insulin resistance, NlDDM, metabolic syndrome and cancer, and complications associated with these diseases and disorders.
